ArticleFrontiers in medicine2020
Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Single-cell RNA-seq analysis reveals microenvironmental infiltration of myeloid cells and pancreatic prognostic markers in PDAC.Discover oncology · 2025Article
- Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by SingleCell RNA Sequencing and its Implications for Prognosis and Therapeutic Response.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Review
- Integrated analyses reveal the diagnostic and predictive values of COL5A2 and association with immune environment in Crohn's disease.Genes and immunity · 2024Article
- Immune landscape of hepatocellular carcinoma tumor microenvironment identifies a prognostic relevant model.Heliyon · 2024Article
- CD79A work as a potential target for the prognosis of patients with OSCC: analysis of immune cell infiltration in oral squamous cell carcinoma based on the CIBERSORTx deconvolution algorithm.BMC oral health · 2023Article
- Six immune-related promising biomarkers may promote hepatocellular carcinoma prognosis: a bioinformatics analysis and experimental validation.Cancer cell international · 2023Article
- Artificial intelligence and machine learning approaches using gene expression and variant data for personalized medicine.Briefings in bioinformatics · 2022Review
- ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma.Translational oncology · 2022Article
- A novel prognostic model based on single-cell RNA sequencing data for hepatocellular carcinoma.Cancer cell international · 2022Article
- MJDs family members: Potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Deciphering Cell-Type-Specific Gene Expression Signatures of Cardiac Diseases Through Reconstruction of Bulk Transcriptomes.Frontiers in cell and developmental biology · 2022Article
- NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis.Oxidative medicine and cellular longevity · 2022Article
- A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.Journal of immunology research · 2022Article
- Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Immune classification of osteosarcoma.Mathematical biosciences and engineering : MBE · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a commonly diagnosed cancer with high mortality rates. The immune response plays an important role in the progression of HCC. Immunotherapies are becoming an increasingly promising tool for treating cancers. Advancements in scRNA-seq (single-cell RNA sequencing) have allowed us to identify new subsets in the immune microenvironment of HCC. Yet, distribution of these new cell types and their potential prognostic value in bulk samples from large cohorts remained unclear. This study aimed to investigate the tumor-infiltration and prognostic value of new cell subsets identified by a previous scRNA-seq study in a TCGA HCC cohort using CIBERSORTx, a machine learning method to estimate cell proportion and infer cell-type-specific gene expression profiles. We observed different distributions of tumor-infiltrating lymphocytes between tumor and normal cells. Among these, the CD4-GZMA cell subset showed association with prognosis (log-rank test,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.